
Pretest probability dictates the entire diagnostic workflow for Cushing syndrome by guiding appropriate patient selection for screening and preventing false positives from incidentalomas or physiological hypercortisolism. Because diagnostic tests carry distinct false-positive rates when applied to low-risk populations, initial biochemical evaluation must be strictly reserved for patients with recognizable clinical stigmata or progressive multisystem manifestations. Quantifying clinical probability prevents the diagnostic cascade of unindicated testing, ensuring that abnormal screening results reflect true autonomous cortisol excess rather than benign physiological mimics or stress-induced alterations.
Weitere Episoden von „Endocrine Deep Dives“



Verpasse keine Episode von “Endocrine Deep Dives” und abonniere ihn in der kostenlosen GetPodcast App.








